These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33821346)

  • 1. The Clinical Utility of DCISionRT
    Shah C; Bremer T; Cox C; Whitworth P; Patel R; Patel A; Brown E; Gold L; Rock D; Riley L; Kesslering C; Brown S; Gabordi R; Pellicane J; Rabinovich R; Khan S; Templeton S; Majithia L; Willey SC; Wärnberg F; Gerber NK; Shivers S; Vicini FA
    Ann Surg Oncol; 2021 Oct; 28(11):5974-5984. PubMed ID: 33821346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Clinical Utility of a 7-Gene Biosignature on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery: An Updated Analysis of the DCISionRT
    Shah C; Whitworth P; Vicini FA; Narod S; Gerber N; Jhawar SR; King TA; Mittendorf EA; Willey SC; Rabinovich R; Gold L; Brown E; Patel A; Vargo J; Barry PN; Rock D; Friedman N; Bedi G; Templeton S; Brown S; Gabordi R; Riley L; Lee L; Baron P; Majithia L; Mirabeau-Beale KL; Reid VJ; Hirsch A; Hwang C; Pellicane J; Maganini R; Khan S; MacDermed DM; Small W; Mittal K; Borgen P; Cox C; Shivers SC; Bremer T
    Ann Surg Oncol; 2024 Sep; 31(9):5919-5928. PubMed ID: 38916700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Biological Signature DCISionRT Use for DCIS Treatment.
    Kim H; Vargo JA; Smith KJ; Beriwal S
    Clin Breast Cancer; 2021 Jun; 21(3):e271-e278. PubMed ID: 33218957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma
    Dabbs D; Mittal K; Heineman S; Whitworth P; Shah C; Savala J; Shivers SC; Bremer T
    Front Oncol; 2023; 13():1069059. PubMed ID: 37274253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of different radiotherapy strategies after breast conserving surgery in patients with ductal carcinoma in situ (DCIS).
    Wärnberg F; Wadsten C; Karakatsanis A; Olofsson Bagge R; Holmberg E; Lindman H; Sawyer E; Vicini F; Mann GB; Karlsson P
    Acta Oncol; 2023 Sep; 62(9):1045-1051. PubMed ID: 37571927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a Ductal Carcinoma
    Weinmann S; Leo MC; Francisco M; Jenkins CL; Barry T; Leesman G; Linke SP; Whitworth PW; Patel R; Pellicane J; Wärnberg F; Bremer T
    Clin Cancer Res; 2020 Aug; 26(15):4054-4063. PubMed ID: 32341032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score™ result.
    Alvarado M; Carter DL; Guenther JM; Hagans J; Lei RY; Leonard CE; Manders J; Sing AP; Broder MS; Cherepanov D; Chang E; Eagan M; Hsiao W; Schultz MJ
    J Surg Oncol; 2015 Jun; 111(8):935-40. PubMed ID: 26031501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local treatment options for young women with ductal carcinoma in situ: A systematic review and meta-analysis comparing breast conserving surgery with or without adjuvant radiotherapy, and mastectomy.
    Chien JC; Liu WS; Huang WT; Shih LC; Liu WC; Chen YC; Chou KJ; Shiue YL; Lin PC
    Breast; 2022 Jun; 63():29-36. PubMed ID: 35299032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS.
    Rakovitch E; Parpia S; Koch A; Grimard L; Soliman H; Stevens C; Perera F; Kong I; Senthelal S; Anthes M; Wiebe E; Cao J; Goldberg M; Smith S; Spadafora L; Whelan TJ
    Breast Cancer Res Treat; 2021 Jul; 188(1):133-139. PubMed ID: 33830392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy.
    Vicini FA; Mann GB; Shah C; Weinmann S; Leo MC; Whitworth P; Rabinovitch R; Torres MA; Margenthaler JA; Dabbs D; Savala J; Shivers SC; Mittal K; Wärnberg F; Bremer T
    Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):93-102. PubMed ID: 36115740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multigene Expression Assay and Benefit of Radiotherapy After Breast Conservation in Ductal Carcinoma in Situ.
    Rakovitch E; Nofech-Mozes S; Hanna W; Sutradhar R; Baehner FL; Miller DP; Fong C; Gu S; Tuck A; Sengupta S; Elavathil L; Jani PA; Bonin M; Chang MC; Slodkowska E; Anderson JM; Cherbavaz DB; Shak S; Paszat L
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 30053207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ.
    Manders JB; Kuerer HM; Smith BD; McCluskey C; Farrar WB; Frazier TG; Li L; Leonard CE; Carter DL; Chawla S; Medeiros LE; Guenther JM; Castellini LE; Buchholz DJ; Mamounas EP; Wapnir IL; Horst KC; Chagpar A; Evans SB; Riker AI; Vali FS; Solin LJ; Jablon L; Recht A; Sharma R; Lu R; Sing AP; Hwang ES; White J;
    Ann Surg Oncol; 2017 Mar; 24(3):660-668. PubMed ID: 27704370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy.
    Rakovitch E; Nofech-Mozes S; Hanna W; Sutradhar R; Gu S; Fong C; Tuck A; Youngson B; Miller N; Done SJ; Chang MC; Sengupta S; Elavathil L; Jani PA; Bonin M; Lalani N; Paszat L
    Breast; 2018 Feb; 37():181-186. PubMed ID: 28781102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Biological Signature for Breast Ductal Carcinoma
    Bremer T; Whitworth PW; Patel R; Savala J; Barry T; Lyle S; Leesman G; Linke SP; Jirström K; Zhou W; Amini RM; Wärnberg F
    Clin Cancer Res; 2018 Dec; 24(23):5895-5901. PubMed ID: 30054280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis.
    Wang SY; Kuntz K; Tuttle T; Kane R
    Breast Cancer Res Treat; 2010 Nov; 124(2):393-402. PubMed ID: 20848183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.
    Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS
    Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple foci of microinvasion is associated with an increased risk of invasive local recurrence in women with ductal carcinoma in situ treated with breast-conserving surgery.
    Rakovitch E; Sutradhar R; Lalani N; Nofech-Mozes S; Gu S; Goldberg M; Hanna W; Fong C; Paszat L
    Breast Cancer Res Treat; 2019 Nov; 178(1):169-176. PubMed ID: 31325071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is higher dose radiation necessary for positive resection margin after breast-conserving surgery for breast cancer?
    Cho WK; Choi DH; Park W; Kim H; Cha H
    Breast; 2019 Oct; 47():16-21. PubMed ID: 31265973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation Therapy Following Breast Conserving Surgery for Ductal Carcinoma in situ: Yes or No?
    Stoleru LS; Stoleru S
    Chirurgia (Bucur); 2017; 112(4):403-412. PubMed ID: 28862116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.